Innovative Humanized Nanobody Targeting TFRC and TNF for Alzheimer's Disease Therapy

VHH-P792 is a novel humanized nanobody therapeutic candidate currently in the Biological Testing stage, designed for the potential treatment of Alzheimer's disease. This innovative molecule targets transferrin receptor (TFRC) and tumor necrosis factor (TNF), two proteins with significant roles in neurodegenerative disease pathogenesis and neuroinflammation. By harnessing the selectivity and affinity of nanobodies, VHH-P792 aims to modulate critical pathways involved in Alzheimer's disease, offering a promising new strategy addressing both disease progression and associated neuroinflammatory mechanisms.

Licensing Opportunity

VHH-P792 is available for out-licensing and partnership opportunities. We welcome collaborations with pharmaceutical and biotechnology companies interested in advancing novel nanobody therapeutics for Alzheimer's disease and related indications.

Development Phase

Modality

VHH-P792 is a heterotrimeric construct engineered by fusing a humanized nanobody against TFRC centrally with humanized nanobodies targeting TNF at both termini. Leveraging the compact single-domain structure of nanobodies, VHH-P792 offers enhanced molecular stability, excellent tissue penetration, and the potential for efficient blood-brain barrier traversal—attributes particularly relevant to addressing central nervous system diseases like Alzheimer's disease. The modular, small-sized nanobody format allows for robust bioavailability and targeting precision, supporting the development of advanced therapeutics where traditional antibodies may face limitations in brain delivery.

Target

TFRC is a transmembrane glycoprotein involved in cellular iron uptake, broadly expressed in proliferative cells, including brain endothelial cells and neurons. TNF is a pro-inflammatory cytokine playing a pivotal role in the regulation of inflammation and immune responses within the central nervous system. Overexpression of TFRC and dysregulation of TNF in the brain are implicated in Alzheimer's disease progression, promoting neurodegeneration and chronic inflammation. Targeting TFRC facilitates nanobody delivery across the BBB, while direct antagonism of TNF reduces pathological neuroinflammation. VHH-P792’s dual targeting of TFRC and TNF positions it strategically for disease modification in Alzheimer's disease, making it a highly attractive asset in the neurodegenerative field.

Mechanism of Action

VHH-P792 exerts its therapeutic effect through simultaneous engagement of TFRC and TNF. The nanobody moiety targeting TFRC facilitates receptor-mediated transcytosis, enhancing brain penetration. Once across the BBB, VHH-P792's anti-TNF arms neutralize TNF activity, modulating central neuroinflammatory pathways implicated in Alzheimer's disease. This dual-action approach interrupts disease-promoting signaling cascades at the neurovascular interface. As a nanobody platform, VHH-P792 can be further adapted into advanced modalities, including bispecific formats, ADCs, or multifunctional constructs, expanding its potential across various neuroinflammatory and neurodegenerative conditions.

Alzheimer's Disease

Alzheimer's disease is the most common cause of dementia, characterized by progressive cognitive decline and memory impairment. It represents a major global health challenge, especially among the aging population. Current treatment strategies encompass symptomatic agents affecting neurotransmitter modulation or amyloid metabolism; however, these approaches do not sufficiently address underlying neuroinflammation or prevent disease progression. Major unmet needs include effective intervention in neuroinflammatory processes and better delivery of biologics across the blood-brain barrier. VHH-P792 directly targets key mechanisms of Alzheimer's pathology via TFRC-mediated CNS delivery and TNF inhibition, representing an advanced strategy to overcome current therapeutic barriers and meet critical care gaps in Alzheimer’s disease.